CD19 and leukemia: As a result, patients who receive low-affinity CD19-CAR-T cell treatment appear to be at a higher risk to experience CD19low and CD19-negative leukemia recurrence which is less common in high-affinity CD19-CAR-T cell therapy [2,97].